New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat

Anthony R Sloan; Mihika Thapliyal; Justin D Lathia

doi:10.1158/1078-0432.CCR-23-3051

New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat

Clin Cancer Res. 2024 Feb 1;30(3):477-479. doi: 10.1158/1078-0432.CCR-23-3051.

Authors

Anthony R Sloan^#^{1

2}, Mihika Thapliyal^#^{1

3}, Justin D Lathia^{1

2

3

4}

Affiliations

¹ Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
² Case Comprehensive Cancer Center, Cleveland, Ohio.
³ Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.
⁴ Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio.

^# Contributed equally.

Abstract

Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized cancer therapy for some advanced cancers, but success is predicated on identifying the correct cell surface target. In a recent article, the authors leveraged the cancer stem cell surface antigen CD133 to develop a CAR-T therapy for brain metastasis. See related article by Kieliszek et al., p. 554.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Brain Neoplasms* / metabolism
Brain Neoplasms* / therapy
Humans
Immunotherapy
Immunotherapy, Adoptive*
Receptors, Antigen, T-Cell / metabolism
T-Lymphocytes

Substances

Receptors, Antigen, T-Cell

Abstract

Publication types

MeSH terms

Substances

Grants and funding